secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2026-05-11T20:07:10+00:00
Accession:  0001746473-26-000088
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q1 net loss $20M; doses first patient in Phase 1b FORTIFY trial
--------------------------------------------------------------------------------

- Q1 net loss $20.0M vs $56.2M prior year; R&D expense $13.6M (down from $43.4M) due to bexotegrast termination and reduced headcount.
- Cash, equivalents and short-term investments $172.4M; expected to fund operations into H2 2028.
- First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027.
- Updated Phase 1 data at AACR showed deepening responses: one complete response, two partial responses in checkpoint-refractory tumors.
- Integrin-targeted delivery platform advancing for siRNA delivery to skeletal muscle; preclinical proof-of-concept ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/0001746473-26-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000088/plrx-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001746473-26-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer